ライフサイエンスコーパス: seronegative

1 urrent with MOG antibodies, and 5 (10%) were seronegative.

2 omparable to those of subjects who were Ad26 seronegative.

3 hether the subjects were CMV seropositive or seronegative.

4 who were HPV16 E6 seropositive compared with seronegative.

5 t of whose baseline samples were found to be seronegative.

6 and by 3 months post-infection the bats are seronegative.

7 93 cases were seropositive and 67 cases were seronegative.

8 ease for individuals who are vaccinated when seronegative.

9 for the seropositives and 11.1 years for the seronegatives.

10 Chagas cardiomyopathy, and among 488 T cruzi seronegatives, 24 (5%) had cardiomyopathy, for an incide

11 In those who were type-2 seronegative, 42 (100%) of 42 seroconverted after GlaxoS

12 A total of 52 602 HCV seronegative, 9508 HCV viremic, and 913 HCV aviremic sub

13 In seronegative acute HIV infection, CD8(+) T cell counts i

14 tivity, was evident in the lamina propria of seronegative acutely HIV-infected patients.

15 overall prevalence was 42%, with 28% in HIV-seronegative adults and 71% in HIV-seropositive adults (

16 We followed A(H1N1)pdm09-seronegative adults through two influenza seasons (2009-

17 Dec 10, 2010, and June 25, 2011, 11 897 HIV-seronegative adults were enrolled in SHIMS and 11 232 (9

18 lication of the pLAIV viruses we observed in seronegative adults.

19 greater risk for cardiovascular disease than seronegative adults.

20 ately to highly restricted in replication in seronegative adults; we sought to determine the biologic

21 ety profile when administered to healthy HIV-seronegative African girls and young women.

22 Among PWID deemed seronegative after screening, there is no sustained tren

23 galovirus (CMV)-seronegative donor for a CMV-seronegative allogeneic hematopoietic stem cell transpla

24 of 8.3 years (range, 0-26 years), 117 (45%) seronegative and 219 (67%) seropositive patients died.

25 The 258 Toxoplasma seronegative and 324 seropositive recipients differed in

26 nts (PHIP) were enrolled, as well as 26 HCMV-seronegative and 39 HCMV-seropositive healthy controls.

27 HIV-1 envelop (Env) vaccine in baseline Ad26-seronegative and Ad26-seropositive healthy volunteers.

28 All were pretransplantation EBV seronegative and asymptomatic when diagnosed during surv

29 -seronegative pregnant women, as well as CMV-seronegative and CMV-seropositive healthy adults, were i

30 healthy adult volunteers who were previously seronegative and experimentally infected with seasonal i

31 viral therapy who were HSV-2 seropositive or seronegative and HIV-uninfected controls were analyzed b

32 es for HPV-6, -11, -16, and -18, among those seronegative and HPV DNA negative for each type.

33 Transfusion of CMV-seronegative and leukoreduced blood products effectively

34 of 0.0% (95% CI, 0.0%-0.3%) per unit of CMV-seronegative and leukoreduced blood.

35 e for VCT; 1999 (24%) clients were initially seronegative and returned for another test.

36 negative responders compared with HRP-IIIgG3-seronegative and SE36IgG1-seropositive responders.

37 Genetic sharing between seronegative and seropostive RA (P < 1 x 10(-9)) had sig

38 ll TDF IVR-treated macaques (n = 6) remained seronegative and simian-HIV RNA negative after 16 weekly

39 seropositive or ST-positive subjects than in seronegative and ST-negative subjects.

40 sAg-seronegatives, including 18,541 anti-HCV seronegatives and 1095 anti-HCV seropositives.

41 One year after MMR3 receipt, no subject was seronegative, and 10 of 617 (1.6%) had low neutralizing

42 nth after MMR3 receipt, 1 subject (0.2%) was seronegative, and 6 (0.9%) had low neutralizing antibodi

43 more likely to be HPyV9-seropositive but MCV-seronegative, and HPyV7 seropositivity was associated wi

44 id not differ significantly in seropositive, seronegative, and statin-associated cases.

45 total of 2,139 HBsAg-seropositive, anti-HCV-seronegative, and treatment-naive participants without l

46 were also detected in Triplex-vaccinated CMV-seronegatives, and in DryVax-vaccinated subjects.

47 als immunized with the empty Ad5 vector, Ad5-seronegative animals immunized with the Ad5 SIV vaccine,

48 immunized with the Ad5 SIV vaccine, and Ad5-seronegative animals immunized with the empty Ad5 vector

49 the 36 seropositive animals and none of the seronegative animals.

50 Compared with anti-HCV seronegatives, anti-HCV seropositives had higher mortali

51 in a G1P[8] rotavirus vaccine trial who were seronegative at baseline, anti-rotavirus immunoglobulin

52 In the BMCS, 1372 people were seronegative at baseline; 1259 (92%) had more than one f

53 d from acutely symptomatic patients who were seronegative at presentation.

54 Most viraemic donors were seronegative at the time of donation.

55 ); in recipients who were Epstein-Barr virus-seronegative at the time of transplant and at risk of pr

56 active IVDU donor who was hepatitis C virus seronegative at time of donation, but was found to be vi

57 recipients who were Epstein-Barr virus (EBV) seronegative at transplantation (SIR 3.93).

58 an infected baby was 4-fold higher in women seronegative before their pregnancy (P = .021).

59 1-year follow-up among patients who were HEV seronegative before transplantation, giving an annual in

60 ainst DENV-3 and DENV-4 in children who were seronegative before vaccination.

61 ared with HIV-infected subjects who were HCV seronegative, both HCV viremic and HCV aviremic individu

62 starting ART before 12 weeks of age were HIV seronegative by almost 2 years of age.

63 At 1 day postinoculation, a seronegative calf (contact animal) was added to each of

64 IgG-positive cases (6 of 7 improved) than in seronegative cases (7 of 25 improved; P= .02).

65 ivity increased PPV to 100% but excluded all seronegative cases (approximately 15% of all RA cases).

66 a subgroup of seropositive-like cases within seronegative cases (PBUHMBOX = 0.008; 2,406 seronegative

67 Case definitions inclusive of seronegative cases had PPVs between 59.6% and 63.6%.

68 cluded in the differential diagnosis even in seronegative cases, although it is not typical for hydat

69 omparison of GlyRalpha1-IgG seropositive and seronegative cases.

70 om an added gene was previously evaluated in seronegative children as a bivalent intranasal RSV/HPIV3

71 was previously shown to be well tolerated by seronegative children but was insufficiently immunogenic

72 After a 2003 serosurvey, 130 originally seronegative children received one dose of virosomal HAV

73 red in the management of patients with HBeAg-seronegative chronic hepatitis B.

74 o probable and confirmed survivors and their seronegative contacts.

75 49 probable and confirmed survivors and 157 seronegative contacts.

76 m 46 HIV-seropositive individuals and 69 HIV-seronegative control individuals.

77 pants contributed 20 477 visits and 2808 HIV-seronegative control participants contributed 27 409 vis

78 s of celiac disease and age- and sex-matched seronegative controls (1:2).

79 280 KSHV-seropositive controls, and 576 KSHV-seronegative controls composing discovery and validation

80 g follow-up and 464 individually matched HIV-seronegative controls were selected from 5 cohorts of wo

81 ted with reduced HIV-1 acquisition among HIV-seronegative controls with high but not low HIV-1 exposu

82 , and 281 treated without SVR), and 2503 HCV-seronegative controls.

83 encephalitis, compared with activity in HIV-seronegative controls.

84 notyped in 504 HIV-1 infected cases, and 343 seronegative controls.

85 mong behaviorally HIV-infected young men and seronegative controls.

86 risk among donor CMV-seropositive, recipient-seronegative (D(+)/R(-)) patients.

87 -14, and 15-22 months of age, the proportion seronegative decreased from 8.5% to 3.2%, 2.4%, and 1.5%

88 k is greatest in seropositive recipient (R+)/seronegative donor (D-) transplants and is exacerbated b

89 The use of a cytomegalovirus (CMV)-seronegative donor for a CMV-seronegative allogeneic hem

90 stimulation in vitro or engineered from HCV-seronegative donor T cells by transduction of a lentivir

91 ecipients who underwent allograft from a CMV-seronegative donor, cases of CMV seropositivity of the d

92 higher risk of chronic GVHD than those with seronegative donors (40.8% v 31.0%, respectively; P < .0

93 val as patients who received grafts from EBV-seronegative donors (hazard ratio [HR], 1.05; 95% CI, 0.

94 Seropositive patients with seronegative donors did not have an increased risk of GV

95 ubjects differed significantly from those of seronegative donors for all 3 immunodominant proteins, G

96 om 439 subjects in Jamaica, including HTLV-I-seronegative donors, ACs, and ATL and HAM/TSP patients.

97 T cells and MCs from CMV-seropositive or CMV-seronegative donors, and for antigen uptake.

98 .92; 95% CI, .86-.98; P < .01) compared with seronegative donors, if they had received myeloablative

99 al [CI], 1.06-1.21; P < .0001) compared with seronegative donors, whereas no difference was seen in p

100 tectable in 10 HLA diverse, HIV-1-unexposed, seronegative donors.

101 s receiving grafts from CMV-seropositive or -seronegative donors.

102 V event compared with NKG2C(+) NK cells from seronegative donors.

103 retory tissues of 44 CMV seropositive and 28 seronegative donors.

104 mes of autoantibody-positive individuals and seronegative FDRs clustered together but separate from t

105 Furthermore, subjects with autoantibodies, seronegative FDRs, and new-onset patients had different

106 iversity were evident in seropositive versus seronegative FDRs.

107 re, 0 [range, 0-5]; P = .007), patients with seronegative findings (n = 28) (median visual score, 1.0

108 me that was similar to that of patients with seronegative findings.

109 Patients with STM who were seronegative for AQP4-IgG among an Olmsted County popula

110 iated with subclinical infection in children seronegative for DENV at enrollment, for whom a second-d

111 r 2010, 582 MSM aged 18 to 40 years who were seronegative for HAV were enrolled in the study.

112 Heterosexual men and women who were seronegative for HIV-1 and HSV-2 and at high risk for HI

113 d volunteers aged at least 45 years who were seronegative for HIV-1 from the established Ugandan Gene

114 lthy individuals (aged 18-45 years) who were seronegative for HIV-1.

115 We evaluated sera from 30 women seronegative for HSV-1 and HSV-2 who were immunized with

116 Subjects had been previously selected to be seronegative for HSV-1 and HSV-2.

117 1767), healthy African girls and young women seronegative for human immunodeficiency virus (HIV) were

118 Of 662 subjects at baseline, 1 (0.2%) was seronegative for MeV-neutralizing antibodies (level, <8

119 Of the 107 serum pairs from infants who were seronegative for RV IgA at enrollment, we observed a str

120 At month 84, in women seronegative for the corresponding HPV type in the accor

121 analysis was done for participants who were seronegative for the given type at baseline.

122 raction), compared with individuals who were seronegative for these HPV types.

123 N9) virus hemagglutinins (HAs) despite being seronegative for these viruses in standard hemagglutinat

124 Of actual donors with IRB, 393 were seronegative for viral markers at time of donation.

125 samples from enrolled subjects who remained seronegative from both the placebo and active treatment

126 ean concentrations (GMCs) and the proportion seronegative (GMC <150 mIU/mL) were derived by age at fi

127 y number = 5.93, range = 1.85-9.21) than the seronegative group (mean log copy number = 2.41, range =

128 ate between the VGKC-complex subgroup versus seronegative group.

129 ences between HTLV-1-seropositive and HTLV-1-seronegative groups were apparent in childhood presentat

130 The features of seropositive versus seronegative groups were compared and binary logistic re

131 apy were also comparable in seropositive and seronegative groups.

132 stvaccination and higher in human CMV (HCMV)-seronegative (HCMV(-)) individuals than in HCMV-seroposi

133 cohort of HIV-infected subjects who were HCV seronegative, HCV viremic (detectable HCV RNA), or HCV a

134 two and 28 urine samples from confirmed and seronegative healthy human subjects, respectively were i

135 HSV-1/HSV-2-seropositive individuals and 47 seronegative healthy individuals (negative controls).

136 Four CMV-seronegative healthy volunteers and three allogeneic HSC

137 Sixty Ad26-seronegative, healthy, HIV-uninfected subjects were enro

138 The highest rates for LAR were in seronegative hepatitis (17%), primary biliary cirrhosis

139 Seronegative hepatitis--non-A, non-B, non-C, non-D, non-

140 resistance to HIV-1 infection in HIV-exposed seronegative (HESN) individuals is suggested to be assoc

141 ates of resistance to HIV-1 in HIV-1-exposed seronegative (HESN) individuals with consistently high e

142 responses, amongst 2 cohorts of HIV-exposed seronegative (HESN) individuals.

143 gest cohort of patients treated during acute seronegative HIV infection (AHI) in whom RCI has been st

144 occur both with PrEP initiation during acute seronegative HIV infection and in PrEP breakthrough infe

145 iral loads below detection (n = 11), and HIV-seronegative (HIV(-)) individuals (n = 16).

146 nyan female sex workers (FSWs) (n = 20), HIV-seronegative (HIV-) FSWs (n = 17), and HIV(-) lower-risk

147 Forty-eight Ad5 and Ad48 seronegative, HIV-uninfected subjects were enrolled in a

148 Here, we demonstrate that seronegative immune repertoires contain antibodies that

149 HIV-infected women who were HPV DNA and HPV seronegative, immune responses to HPV vaccination were g

150 donation and age-, sex-, and period-matched seronegatives in 1996 to 2002 in the Brazilian cities of

151 There were 19,636 HBsAg-seronegatives, including 18,541 anti-HCV seronegatives a

152 the infectiousness of HIV-seropositive and -seronegative index cases have been performed in sub-Saha

153 -B40 group was a risk factor for PTLD in EBV-seronegative individuals (OR = 8.38, 95% CI = 2.18-32.3)

154 ed alleles compared with 8 (28.6%) of the 28 seronegative individuals (P = .04).

155 censed dengue vaccine that failed to protect seronegative individuals from breakthrough or enhanced d

156 unningham virus DNA was detected in urine of seronegative individuals in a research-grade assay.

157 (PrEP) by human immunodeficiency virus (HIV)-seronegative individuals reduces the risk of acquiring H

158 Eighteen HIV-1 infected HSV-2-seronegative individuals were randomly assigned in a dou

159 of a questionnaire at baseline and, for HIV-seronegative individuals, 6 months later.

160 factors for PTLD in EBV-seropositive and EBV-seronegative individuals, respectively.

161 V-specific immune responses in HIV-1-exposed seronegative individuals.

162 arum lysate-seropositive individuals than in seronegative individuals.

163 safe development of nonlive RSV vaccines for seronegative infants and children.

164 on in a prospective study of 406 HSV-2/HIV-1-seronegative Kenyan women, of whom 164 acquired HSV-2.

165 ytomegalovirus (CMV)-specific T cells in CMV-seronegative kidney transplant recipients (KTRs) have be

166 ) Kenyan female sex workers (FSW) and 20 HIV-seronegative lower risk (HIV(-) LR) women.

167 Patients who are seronegative may not satisfy the 2010 criteria despite m

168 e (PfRH5-seropositive median: 71 days, PfRH5-seronegative median: 18 days; P = .001).

169 bine-tenofovir disoproxil fumarate among HIV-seronegative men and transgender women who have sex with

170 ive (iPrEx) study randomly assigned 2499 HIV-seronegative men and transgender women who have sex with

171 tal HSV shedding in HIV-seropositive and HIV-seronegative men and women in Uganda.

172 We randomly assigned HIV-seronegative men and women to receive either tenofovir d

173 tistically between baseline seropositive and seronegative men at any study visit or over the follow-u

174 Among 2044 HSV-2 seronegative men at baseline, the cumulative 72-month HS

175 Each of 36 HCMV-seronegative men received 1 subcutaneous dose of 10, 100

176 e report the effect of FTC/TDF on BMD in HIV-seronegative men who have sex with men and in transgende

177 nsgender women (p=0.31), and 58 (52%) of 111 seronegative MSM (p<0.0001).

178 In HIV-seronegative MSM, syphilis infection was associated with

179 Double-seronegative myasthenia gravis (dSNMG) includes patients

180 in classifying atypical multiple sclerosis, seronegative neuromyelitis optica spectrum disorders and

181 Only 6.5% of patients had "true" seronegative NMO and 6.5% had idiopathic LETM.

182 00%) were based on 92 control samples and 35 seronegative NMO/SD patient samples.

183 ly specific assays, leaving 35 patients with seronegative NMO/spectrum disorder (SD).

184 both appropriate control samples and defined seronegative NMOSD samples is essential to evaluate thes

185 previously detected in Chinese patients with seronegative (non-A-E) hepatitis.

186 Dogs that were seronegative on entry but seroconverted while in the ken

187 nts who cannot be clinically identified from seronegative ones.

188 significantly higher risk for all other EBV seronegative organ transplant groups and also for EBV se

189 Seronegative, parous women represent the highest risk po

190 Compared to seronegative participants (age- and sex-adjusted mortali

191 We compared (1) HCV-seropositive with HCV-seronegative participants and (2) HCV-viremic with succe

192 ce antigen (HBsAg)-seropositive and anti-HCV-seronegative participants from the Risk Evaluation of Vi

193 tocol analysis at month 7, 100% of initially seronegative participants in the vaccine group were sero

194 ropositive and incidence density-matched HCV-seronegative participants of the Swiss HIV Cohort Study

195 e changes between HCV seroconverters and HCV-seronegative participants while adjusting for baseline c

196 Among 57 baseline EBV-seronegative participants, 9 developed EBV primary infec

197 Ag-seropositive participants and 1,708 HBeAg-seronegative participants, respectively.

198 ots in seroconverters and a random sample of seronegative participants.

199 articipants while it was only seen in 14% of seronegative participants.

200 ouples in which HIV-1 was transmitted to the seronegative partner during the study; control couples (

201 Among 1314 couples in which the HIV-1-seronegative partner was female (median follow-up 18.0 [

202 es in which HIV-1 was not transmitted to the seronegative partner.

203 erpes simplex virus (HSV)-2, and their HIV-1-seronegative partners.

204 We present the case of a 26-year-old HIV-seronegative patient with XDR pulmonary tuberculosis ref

205 sitive unrelated donor is selected for a CMV-seronegative patient.

206 rocephalus in a human immunodeficiency virus-seronegative patient.

207 of reperfusion compared with cytomegalovirus-seronegative patients (-192 versus -63 cells/muL; P=0.00

208 primary infection occurred in 27 of 43 (63%) seronegative patients and reactivation/reinfection in 28

209 ulosis cases may be less infectious than HIV-seronegative patients only when they are smear-negative

210 Seronegative patients receiving seropositive unrelated-d

211 Ninety-six HBV-seronegative patients who completed the vaccination seri

212 Some IgG-seronegative patients who receive an IgG-seropositive al

213 T-cell responses have been described in seronegative patients who test negative for hepatitis C

214 7+) = 0.1, 95% CI = 0.02-1.0), whereas E6/E7 seronegative patients with evidence of HPV in tumor DNA

215 012, we identified in a single center 18 HIV-seronegative patients with HHV-8-related CD.

216 In seronegative patients with seropositive donors, the HR f

217 nrolled HIV-negative and human herpesvirus-8-seronegative patients with symptomatic multicentric Cast

218 the infectiousness of HIV-seropositive and -seronegative patients with tuberculosis to their househo

219 Of 27 JCV seronegative patients, 10 (37%) had JCV viruria.

220 other causes need to be excluded in NMO-IgG-seronegative patients.

221 e aggressive disease course as compared with seronegative patients.

222 a classic picture of ALS, similar to that of seronegative patients.

223 Stored serum specimens from "seronegative" patients were retested with recombinant hu

224 HSV-2-seropositive, HIV-seronegative people were enrolled at the University of W

225 donors with low levels i(4 of 30), and 0% of seronegative persons (0 of 32).

226 with low JCV serostatus (2 of 93), and 0% of seronegative persons (0 of 43).

227 s with undiagnosed celiac disease vs 0.1% in seronegative persons (P < .01).

228 HSV-specific CD4 T cells recovered from HSV-seronegative persons can be explained, in part, by such

229 Of 365 HSV-2-seronegative persons, 68 acquired HSV-2, with 24 receivi

230 valACV suppresses VL in HIV-1 infected HSV-2-seronegative persons.

231 he intestinal mucosal barrier already in the seronegative phase of acute HIV infection, thereby induc

232 t stages of HIV infection, starting from the seronegative phase.

233 ore samples from seropositive pigs than from seronegative pigs.

234 early second trimester in two of three rhCMV-seronegative pregnant females.

235 V-associated sequelae occurred in four rhCMV-seronegative pregnant macaques that were CD4(+) T-cell d

236 These results mean that seronegative pregnant women have options to prevent feta

237 A total of 287 HSV-2-seronegative pregnant women were recruited, and their pa

238 CMV-seronegative pregnant women, as well as CMV-seronegative

239 The overall weighted seronegative prevalence of VZV was 2.2% for the pooled N

240 Initially HCV-seronegative PWID (n = 208) were followed prospectively

241 e among HCV seroconverters but not among HCV-seronegative PWID (P < .05).

242 seronegative cases (PBUHMBOX = 0.008; 2,406 seronegative RA cases).

243 ation was found for sugar-sweetened soda and seronegative RA.

244 Early-onset disease was associated with EBV-seronegative recipient status, EBV-positive histology, a

245 2 HHV8-mismatch patients (seropositive donor/seronegative recipient) developed a primary infection, o

246 For CMV-seronegative recipients (R(-)) with CMV-seropositive don

247 orted by the increased PCN risk in young EBV seronegative recipients and the presence of EBV in tumor

248 Seronegative recipients are at high risk for developing

249 ght seropositive recipients and one of three seronegative recipients displayed peripheral blood CD8+

250 Only 7 of 12 (58.3%) seronegative recipients of a seropositive donor (positiv

251 Nearly 25% of EBV seronegative recipients of EBV+ donors at ages 4-7 at tr

252 ipients of kidney transplants, including 168 seronegative recipients receiving organs from seropositi

253 PTLD occurring in EBV-seronegative recipients was associated with EBV nuclear

254 Compared with CMV-seronegative recipients who underwent allograft from a C

255 ation benefits both the whole population and seronegative recipients.

256 years, we observed (HCV seropositive and HCV seronegative, respectively) 107 and 18 liver events, 41

257 -74) in HRP-IIIgG3-seropositive and SE36IgG1-seronegative responders compared with HRP-IIIgG3-seroneg

258 perimental RhCMV 180.92 inoculation of RhCMV-seronegative rhesus macaques.

259 derly individuals, and occasionally leads to seronegative rheumatoid arthritis-like pathologies.

260 clusion chromatography, we obtained from HCV-seronegative sera a purified fraction enriched in inhibi

261 87 (90%) of 97 infants who were type-3 seronegative seroconverted after intramuscular IPV, and

262 suggesting a major prevention benefit among seronegative sex partners in stable or casual relationsh

263 iciency virus (HIV) participants compared to seronegative (SN) controls.

264 , panuveitis, severe uveitis associated with seronegative spondyloarthropathy, and scleritis in patie

265 ney transplant recipients between 43 CMV IgG-seronegative (sR(-)) and 86 CMV IgG-seropositive (sR(+))

266 riables associated with DNAemia included EBV seronegative status at transplant (p = 0.045), non-White

267 ndividuals with highly exposed, persistently seronegative status can neutralize infection and present

268 Epstein-Barr virus (EBV) seronegative status pretransplant (odds ratio [OR] = 7.6

269 gher for CMV-seropositive as compared to CMV-seronegative subjects and was marginally associated with

270 Four of 85 baseline CMV-seronegative subjects developed asymptomatic primary CMV

271 Four CMV-seronegative subjects developed IFN-gamma responses agai

272 HIV-1-seronegative subjects had no proliferation or IFN-gamma

273 HIV-1-specific T-cell responses in exposed seronegative subjects suggest that a viral breach of the

274 Eighty Ad5-seronegative subjects were randomized to receive 2 x NYV

275 cords and compared among 32 HIV-infected CMV-seronegative subjects, 126 age, CD4 and gender-matched H

276 (ILCs) was similar to that observed in HIV-1-seronegative subjects, and transcription of genes encodi

277 Compared with HCV seronegative subjects, HCV viremic subjects were at incr

278 erapy (HAART), compared with that for 10 HIV-seronegative subjects.

279 monocytes and mDCs from seropositive versus seronegative subjects.

280 monocytes were observed in seropositive and seronegative subjects.

281 and 1 healthy volunteer were viremic but had seronegative test results for JCV antibodies.

282 More specimens from the ART-96W group were seronegative than from the ART-Def group by enzyme immun

283 which HIV-1-susceptible partners were HSV-2 seronegative to estimate the effect of acyclovir on risk

284 6/11/16/18/31/33/35/39/45/51/52/56/58/59 and seronegative to HPV 6/11/16/18 at day 1, and had a norma

285 patients and control group participants were seronegative to IgA antibodies to TG2, endomysium, and d

286 at the seroconversion visit, six (18%) of 33 seronegative transgender women (p=0.31), and 58 (52%) of

287 household contacts of HIV-seropositive and -seronegative tuberculosis cases (relative risk, 0.89; 95

288 proteins and was recently shown to induce in seronegative volunteers a CD4 T cell response largely do

289 ormalities associated with HPV-16/18 between seronegative vs seropositive women (15-25 years) in the

290 hazard ratio (HR) for PTLD if recipient EBV seronegative was 5.005 for KTX, 6.528 for HTX and 2.615

291 SCT patients, 29 349 seropositive and 20 193 seronegative, were identified from the European Group fo

292 re seen in patients when they became MOG-IgG seronegative, whereas a persistent positive serological

293 humans, even though the study subjects were seronegative with respect to the vaccine viruses before

294 The HPTN 064 study enrolled 2067 HIV-seronegative women and 32 HIV-seropositive women with no

295 observed with herpetic lesions; (4) 18 HSV-2 seronegative women at 45 clinic visits.

296 ually randomized superiority trial among HIV-seronegative women at three sites in Malawi with high SP

297 ble genital HIV RNA varied from 73% in HSV-2 seronegative women to 94% in women with herpetic lesions

298 HSV-seronegative women, aged 18-30 years, who were in the co

299 f the general population of HSV-1- and HSV-2-seronegative women, the investigational vaccine was effe

300 f bacterial vaginosis (BV) compared to HSV-2-seronegative women.

301 ort-term renal safety of TDF/FTC PrEP in HIV-seronegative young men and suggest that endocrine disrup